Helicon Group Limited

 
 
     

View in Other Languages

News

Asian Activities Report for October 18, 2011: Algae. Tec Limited (ASX:AEB) to Build Algae Demonstration Plant in Sydney for Alternative Fuel Solutions

🕔10/18/2011 1:03:52 PM 13857

Asian Activities Report for October 18, 2011 includes: Algae. Tec Limited (ASX:AEB) has received regulatory approvals for the development of an algae demonstration plant in the south of Sydney; Helicon Group Limited (ASX:HCG) today announces the execution of a definitive agreement to acquire Aspen Medisys; Alkane Resources Limited (ASX:ALK) has signed an agreement with the NSW Government to receive financial assistance for the infrastructure development of the Tomingley Gold Project in the Central West of NSW; Transerv Energy Limited (ASX:TSV) has completed the initial 10-day test of the Upper Zone at the Warro-4 onshore well in Western Australia; Augur Resources Limited (ASX:AUK) reports extensive gold and copper results from the Randu Kuning prospect, Wonogiri project in Central Java.

Read Full Article

Helicon Group Limited (ASX:HCG) Restructure Set To Reduce Operating Costs By Up To 50%

🕔11/11/2008 1:08:15 PM 6139

HELICON GROUP LIMITED (ASX:HCG) announced today that it has implemented a restructuring and cost reduction program in response to the ongoing delays by the Chinese regulatory authority, the State Food and Drug Administration (SFDA), to grant regulatory approvals across the board and an anticipated slow down in economic activity in China.

Read Full Article

Chinese SFDA Approves Helicon's (ASX:HCG) ReCell(R) Concept And Kit

🕔7/21/2008 5:12:40 PM 8042

Helicon Group Limited (ASX:HCG) is pleased to announce that earlier this month the Chinese State Food and Drug Administration (SFDA) granted approval for the skin regeneration concept and device, ReCell(R), for sale in China.

Read Full Article

Helicon Group Limited (ASX:HCG) Secures Milestone Regulatory Approval In China For Skin Regeneration Medical Technology ReCell(R)

🕔7/3/2008 12:32:43 PM 10092

HELICON GROUP LIMITED (ASX:HCG) today announced that the Chinese State Food and Drug Administration (SFDA) has granted approval for the skin regeneration concept and device, ReCell(R).

Read Full Article

Helicon Group (ASX:HCG) Announce 3rd Party Equity Research Report by Money Cat Consulting

🕔6/5/2008 5:03:34 PM 6123

Helicon Group (ASX:HCG) wishes to inform the market of the release of a third party research report, compiled by Money Cat Consulting, which focuses on the company's core competencies, business model and product acquisitions.

Read Full Article

Helicon Group Limited (ASX:HCG) Present The Company Profile and The China Opportunity

🕔5/21/2008 10:04:30 AM 11079

Helicon Group Limited (ASX: HCG) is a pharmaceutical and healthcare company with an innovative strategy, listed on the Australian Securities Exchange. Its business is to identify and exploit niche market opportunities in the specialty pharmaceutical and healthcare markets of China and North Asia and to participate in the significant growth that has been projected for those markets over the next 20 years.

Read Full Article

Helicon Group Limited (ASX:HCG) Secures Exclusive China Rights For Collatamp G, An Innovative Drug Release Surgical Implant

🕔5/12/2008 2:48:44 PM 6944

HELICON GROUP LIMITED (ASX: HCG) announced today that it had acquired the exclusive licensing rights from EUSA Pharma to Collatamp(R) G for the Chinese market.

Read Full Article

Helicon Group Limited (ASX: HCG) Intensifies Efforts To Extend Product Portfolio With Swiss Based Executive Appointment

🕔1/31/2008 10:04:28 AM 5612

HELICON GROUP LIMITED (ASX: HCG) is pleased to announce the appointment of Anita Wehrli to the position of Business Development Manager based in Switzerland.

Read Full Article

Helicon Group Limited (ASX:HCG) Appoints Aleksandra Gajda To Stakeholder Relations Manager

🕔1/24/2008 2:19:11 PM 5538

HELICON GROUP LIMITED (ASX: HCG) today announced the appointment of Aleksandra Gajda to the position of Stakeholder Relations Manager.

Read Full Article

Helicon Group (ASX:HCG) Shareholder Update - Jewim Pharmaceuticals China

🕔1/14/2008 2:07:32 PM 5968

With the regulatory process well underway in China, Helicon (ASX: HCG) has put the ReCell(R) pre-marketing program into gear with a number of activities over the last few months.

Read Full Article
###

60,878 COMPANY PROFILE VIEWS

  • This Page Viewed: (Last 7 Days: 20) (Last 30 Days: 128) (Since Published: 17827) 

Company Data

    Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology